Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917194 | 1.00 | TACR1 (0.76) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8917204 | 1.00 | TACR1 (0.76) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4938888 | 0.93 | TACR1 (0.65) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4938900 | 0.93 | TACR1 (0.65) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4938892 | 0.93 | TACR1 (0.65) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL31401591 | 0.88 | TACR1 (0.61) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8702339 | 0.88 | TACR1 (0.72) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8702337 | 0.88 | TACR1 (0.72) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8702331 | 0.88 | TACR1 (0.72) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL9294005 | 0.88 | TACR1 (0.68) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-5686615-A | HYDROGENATION OF A PYRIDINE COMPOUND IN THE PRESENCE OF A METAL CATALYST | PFIZER INC (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0436334-B1 | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5332817-A | 3-aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER INC. (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0581777-A1 | STEREOSELECTIVE PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER INC. (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5232929-A | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use | PFIZER INC. (US) | 1993-08-03 | — | — | US | disclosed |
| WO-1992017449-A1 | STEREOSELECTIVE PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0436334-A2 | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER INC. (US) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | TACR1 460/4885CYP2D6 1097/4885KCNH2 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.